nhs healthcare contracts

The London Borough of Hammersmith & Fulham (the Council) is inviting suitably qualified and experienced providers to tender for the delivery of School Health & Wellbeing Services 5–19 (25). This procurement supports the delivery of the Healthy Child Programme (HCP) and aims to improve health outcomes for children, young people, and families across the borough. The services will provide support for children aged 5–19 years, and up to 25 for young people with SEND. The contract estimated value is £1,110,000 – £1,260,000 per annum

Central London Community Healthcare (CLCH) seeks to implement an integrated medical model for Urgent Community Response (UCR), Enhanced Care Home Teams (ECHT), Integrated Case Management (ICM) and Falls Services across Brent and Harrow.<br/><br/>This model aims to enhance operational efficiency, ensure cost-effective resource allocation, and improve patient safety and quality of care across frailty and falls pathways.<br/><br/>The new model consolidates multiple current contracting arrangements, into a single CLCH-procured Frailty Consultant Service, supported by a structured GP cross-cover model.<br/><br/>The provider of the Frailty Consultant Service will provide Consultant(s) that will be the clinically accountable clinician(s) for the integrated Brent and Harrow UCR, ECHT, ICM and Falls services, providing clinical leadership, medical oversight, and strategic direction to ensure consistent, high-quality community care.<br/><br/>Key Aims<br/>• Deliver 52-week consultant clinical accountability and governance across all frailty services.<br/>• Provide expert medical input to complex community cases, admission prevention, and safe discharge planning.<br/>• Lead and support multidisciplinary teams (MDTs) in Brent and Harrow.<br/>• Develop, implement and monitor clinical pathways and escalation processes.<br/>• Strengthen integration between community and acute care, social services and primary care partners.<br/>• Support quality improvement, audit, and staff development initiatives aligned with CLCH’s strategic priorities.<br/><br/>The contract will be for two years with the option to extend for a further one year.

NHS England are seeking specialist external support to deliver a financial improvement programme across AACC through two key approaches: large-scale package-level financial reviews and targeted system deep dives. Please note the following general conditions: • This RFI will help us to refine the requirements, future strategy and understand suppliers potential capabilities in the marketplace. • Should a further competition be undertaken we reserve the right to only invite suppliers who have only initially responded to the RFI • We reserve the right not to proceed with a further competition. • Nothing shall constitute a commitment to ordering unless we undertake a further competition that results in the award of a Call-Off Contract. • Any and all costs associated with the production of such a response either to a RFI or a further competition must be borne by the Supplier. We will not contribute in any way to meeting production costs of any response. • Information contained within this document is confidential and must not be revealed to any third party without prior written consent from us. • No down-selection of Potential Providers will take place as a consequence of any responses or interactions relating to this RFI. • We expect that all responses to this RFI will be provided by Potential Providers in good faith to the best of their ability in the light of information available at the time of their response. • No information provided by a Potential Provider in response to this RFI will be carried forward, used or acknowledged in any way for the purpose of evaluating the Potential Provider, in any subsequent formal procurement process.

This RFI is intended for organisations currently providing QC testing services for medical and related devices within the UK. Responses should describe existing facilities and capabilities that could be deployed to support UKHSA's laboratory operations, particularly during periods of increased demand or public health emergencies. These QC tests relating to Parts 1-2 of the inspection process are to be undertaken at the manufacturing facility. Part 3 testing the performance/functionality of the kits can be undertaken either at the manufacturing site or another mutually agreed appropriate site. Recent procurements of PCR and LFD products have been from manufacturers based in the United Kingdom, United States of America, China, and Italy. Should you wish to respond to this Request for Information, please complete the response questionnaire which is found at the following link: https://atamis-1928.my.salesforce-sites.com/ProSpend__CS_ContractPage?SearchType=Projects&uid=a07Pz00001XIjD5IAL&searchStr=&sortStr=Recently+Published&page=1&filters=&County=

1. The purpose of this document is to enhance the Authority’s understanding of the marketplace and its options for sourcing for a potential future requirement. 2. The issuance of this request for information (RFI) does not constitute a sourcing exercise nor will the Authority pay any costs incurred in the preparation of a response to this RFI. 3. The UK Health Security Agency’s (UKHSA) key objectives for this RFI are: a. understand the ability of the marketplace to fulfil its requirements. b. refine the scope of the requirements to best align to the marketplace; and c. inform the Authority’s chosen route to market to best enable competition 4. The key dates for this RFI are as follows: 1. RFI Published: 27th April 2026 2. RFI Response: 17:0 - 29th May 2026 5. Should you have any questions or queries relating to this RFI, please use the Atamis portal’s messaging centre to direct your questions to us for a response. 6. If a response is not received by the RFI response deadline this will have no impact on your ability to tender for the opportunity in the future. UKHSA will not enter into contracts on the basis of replies to this RFI.   | Description of Scope of Requirements: The UK Health Security Agency (UKHSA) is responsible for protecting the public from infectious diseases, chemical, biological, radiological and nuclear hazards, and other health threats. We provide scientific, operational and strategic leadership nationally, locally, and internationally to strengthen the nation’s health security. UKHSA is assessing opportunities to enhance its existing Quality Control (QC) testing capability through collaboration with UK-based organisations that deliver operational QC services for medical devices and related products (primarily, LFD & PCR testing kits). This Request for Information (RFI) aims to understand the capability, capacity, readiness, and interest of organisations that may be able to support UKHSA’s public health mission during surge periods or emergencies. Objectives: • Identify operational QC testing facilities with available capacity or surge capability. • Assess technical, digital, and governance capabilities for potential collaboration. • Explore commercial models for engagement with UKHSA. This RFI is intended for organisations currently providing QC testing services for medical and related devices within the UK. Responses should describe existing facilities and capabilities that could be deployed to support UKHSA’s laboratory operations, particularly during periods of increased demand or public health emergencies. These QC tests relating to Parts 1–2 of the inspection process are to be undertaken at the manufacturing facility. Part 3 testing the performance/functionality of the kits can be undertaken either at the manufacturing site or another mutually agreed appropriate site. Recent procurements of PCR and LFD products have been from manufacturers based in the United Kingdom, United States of America, China, and Italy. Should you wish to respond to this Request for Information, please complete the response questionnaire which is found at the following link: https://atamis-1928.my.salesforce-sites.com/ProSpend__CS_ContractPage?SearchType=Projects&uid=a07Pz00001XIjD5IAL&searchStr=&sortStr=Recently+Published&page=1&filters=&County=

The British Embassy Beirut requires a provision of medical, life, and workmen compensation insurance for its Country-Based employed staff at the British Embassy Beirut. The contract duration of the said provision shall be for an inital of one (1) year from 01 August 2026 to 31 July 2027 with an option to extend for to two (2) additional years to be renewed annualy. The total amount of the provision is £1412696.26

HR&OD Procurement of psychometric tools and services for use in selection and development activities, including associated in-house training and development.

NLFT is seeking to procure an Ambient Voice Technology (AVT) solution as part of its digital transformation strategy. The aim is to reduce clinicians’ administrative burden and improve the timeliness and quality of clinical documentation across the Trust. At this stage, NLFT is undertaking early market engagement to better understand the current capabilities, maturity, integration and delivery models available within the AVT market. This Request for Information (RFI) is intended to gather insights from suppliers to help shape the Trust’s requirements, approach to implementation, and overall procurement strategy. More information and RFI document can be found here . https://atamis-1928.my.salesforce-sites.com/ProSpend__CS_ContractPage?SearchType=Projects&uid=a07Pz00001bHf7YIAS&searchStr=&sortStr=Recently+Published&page=1&filters=&County=

The contract is expected to initially be delivered for a period of 5 years, at a maximum total budget of up to £16,080,000 including VAT and £13,400,000 GBP excluding VAT. Bids exceeding this limit will be rejected. There is potential to extend the contract for up to two additional years as well as the option to include other aspirational measures (which will be defined in the service specification) meaning the ceiling value has the potential to be higher. Due to the unknowns in advance of holding the premarket engagement session, it is currently expected that the extension value will be a 2 year pro rata of the core 5 year funding, estimated at £5,360,000 excluding VAT. This proposed extension value may also include pro rata funding of any additional aspirational measures invoked in the first 5 years of the contract. For example: If an aspirational annual requirement costing £500,000 per year is invoked in year 5, then the extension funding (if the aspirational measure is continued) will be the above figures plus the additional £500,000 per year. Further to this funding, the final specification will contain a list of aspirational measures which will be expected to be modified into the contract should the need and funding become available. The aspirational intent value, excluding the potential 2 year extension, is unknown at point of drafting this notice, so, an estimated value of £15,000,000 excluding VAT is applied to form the maximum total estimated value AT POINT OF DRAFTING THIS NOTICE. This aspirational intent has the potential to be invoked fully, partially, or not at all, and the Authority cannot guarantee that the successful supplier will be required to do any of the aspirational measures that will be listed in the final specification. The Healthcare Quality Improvement Partnership (HQIP) is seeking to procure the following services for the National Joint Registry (NJR). •NJR data management, solutions, statistical analysis and reporting, and (optional) associated services HQIP is not only looking for organisations to provide these services but also to partner with organisations that can demonstrate the following characteristics: •Strategic and solution orientated •Proactive, responsive and flexible •Ability to add value •Committed to continual improvement •Communicative and effective team player •Innovative Joint replacements have become common and highly successful operations that bring many patients improved mobility and relief from pain. Thousands of such operations take place in the UK every year. A wide range of implants can be used in joint replacement operations and the NJR helps to monitor the performance of these implants and the effectiveness of different types of surgery; improving clinical standards and benefiting patients, clinicians and the orthopaedic industry. The NJR was set up in April 2002 by the Department of Health (DH) and Welsh Government following a National Audit Office report into a failing ‘3M’ hip implant. From 1 April 2008, hosting arrangements for the NJR were transferred from the DH to HQIP. The NJR has collected hip and knee replacement data since April 2003, ankle replacement data since April 2010 and data for elbow and shoulder replacements since April 2012. The DH provided the initial start-up funding for the NJR. However, the system is now self-financing through a subscription charge on each ‘eligible’ hip, knee, ankle, elbow and shoulder implant which is payable by NHS Trusts (England), Health and Social Care Trusts (Northern Ireland), Local Health Boards (Wales) and independent (private) healthcare providers. The cost to the NHS was reduced in 2014 through a contributory financial subscription arrangement with the orthopaedic device industry whereby an annual subscription is charged for provision of the NJR Supplier Feedback service and other bespoke reporting. Since April 2014, the NJR subscription has been invoiced annually and the income managed in a dedicated fund at HQIP, governed by the NJR Board (NJRB). The purpose of the National Joint Registry, which covers England, Wales, Northern Ireland, the Isle of Man, the States of Guernsey and the Channel Islands, is to collect high quality and relevant data about joint replacement surgery in order to provide an early warning of issues relating to patient safety. In a continuous drive to improve the quality of outcomes and ensure the quality and cost-effectiveness of joint replacement surgery, the NJR will monitor and report on outcomes, and support and enable related research. The NJR’s strategic goals are to: •Monitor in real time the outcomes achieved by brand of prosthesis, hospital and surgeon, and highlight where these fall below an expected performance in order to allow prompt investigation and to support follow-up action. •Inform patients, clinicians, providers and commissioners of healthcare, regulators and implant suppliers of the outcomes achieved in joint replacement surgery. •Evidence variations in outcome achieved across surgical practice in order to inform best practice. •Enhance patient awareness of joint replacement outcomes to better inform patient choice and patients' quality of experience through engagement. •Support evidence-based purchasing of joint replacement implants for healthcare providers to support quality and cost effectiveness. •Support suppliers in the routine post-market surveillance of implants and provide information to clinicians, patients, hospital management and the regulatory authorities. Current Expectations - To be Defined Core service provision is expected to include: •Data systems and ingestion •Data processing and cleaning •Dynamic reporting and dashboards •Supplier feedback •Annual report statistical outputs •Outlier detection, reporting and analysis •PROMs and PREMs collection •Service desk and operational support Further details of the existing programme can be found at: https://www.njrcentre.org.uk/ For more information about this opportunity, please visit the eSourcing portal at: https://www.delta-esourcing.com/tenders/UK-UK-London:-Health-services./7449M9X8XA To respond to this opportunity, please click here: https://www.delta-esourcing.com/respond/7449M9X8XA

The contract is expected to initially be delivered for a period of 5 years, at a maximum total budget of up to £16,080,000 including VAT and £13,400,000 GBP excluding VAT. Bids exceeding this limit will be rejected. There is potential to extend the contract for up to two additional years as well as the option to include other aspirational measures (which will be defined in the service specification) meaning the ceiling value has the potential to be higher. Due to the unknowns in advance of holding the premarket engagement session, it is currently expected that the extension value will be a 2 year pro rata of the core 5 year funding, estimated at £5,360,000 excluding VAT. This proposed extension value may also include pro rata funding of any additional aspirational measures invoked in the first 5 years of the contract. For example: If an aspirational annual requirement costing £500,000 per year is invoked in year 5, then the extension funding (if the aspirational measure is continued) will be the above figures plus the additional £500,000 per year. Further to this funding, the final specification will contain a list of aspirational measures which will be expected to be modified into the contract should the need and funding become available. The aspirational intent value, excluding the potential 2 year extension, is unknown at point of drafting this notice, so, an estimated value of £15,000,000 excluding VAT is applied to form the maximum total estimated value AT POINT OF DRAFTING THIS NOTICE. This aspirational intent has the potential to be invoked fully, partially, or not at all, and the Authority cannot guarantee that the successful supplier will be required to do any of the aspirational measures that will be listed in the final specification. The Healthcare Quality Improvement Partnership (HQIP) is seeking to procure the following services for the National Joint Registry (NJR). •NJR data management, solutions, statistical analysis and reporting, and (optional) associated services HQIP is not only looking for organisations to provide these services but also to partner with organisations that can demonstrate the following characteristics: •Strategic and solution orientated •Proactive, responsive and flexible •Ability to add value •Committed to continual improvement •Communicative and effective team player •Innovative Joint replacements have become common and highly successful operations that bring many patients improved mobility and relief from pain. Thousands of such operations take place in the UK every year. A wide range of implants can be used in joint replacement operations and the NJR helps to monitor the performance of these implants and the effectiveness of different types of surgery; improving clinical standards and benefiting patients, clinicians and the orthopaedic industry. The NJR was set up in April 2002 by the Department of Health (DH) and Welsh Government following a National Audit Office report into a failing ‘3M’ hip implant. From 1 April 2008, hosting arrangements for the NJR were transferred from the DH to HQIP. The NJR has collected hip and knee replacement data since April 2003, ankle replacement data since April 2010 and data for elbow and shoulder replacements since April 2012. The DH provided the initial start-up funding for the NJR. However, the system is now self-financing through a subscription charge on each ‘eligible’ hip, knee, ankle, elbow and shoulder implant which is payable by NHS Trusts (England), Health and Social Care Trusts (Northern Ireland), Local Health Boards (Wales) and independent (private) healthcare providers. The cost to the NHS was reduced in 2014 through a contributory financial subscription arrangement with the orthopaedic device industry whereby an annual subscription is charged for provision of the NJR Supplier Feedback service and other bespoke reporting. Since April 2014, the NJR subscription has been invoiced annually and the income managed in a dedicated fund at HQIP, governed by the NJR Board (NJRB). The purpose of the National Joint Registry, which covers England, Wales, Northern Ireland, the Isle of Man, the States of Guernsey and the Channel Islands, is to collect high quality and relevant data about joint replacement surgery in order to provide an early warning of issues relating to patient safety. In a continuous drive to improve the quality of outcomes and ensure the quality and cost-effectiveness of joint replacement surgery, the NJR will monitor and report on outcomes, and support and enable related research. The NJR’s strategic goals are to: •Monitor in real time the outcomes achieved by brand of prosthesis, hospital and surgeon, and highlight where these fall below an expected performance in order to allow prompt investigation and to support follow-up action. •Inform patients, clinicians, providers and commissioners of healthcare, regulators and implant suppliers of the outcomes achieved in joint replacement surgery. •Evidence variations in outcome achieved across surgical practice in order to inform best practice. •Enhance patient awareness of joint replacement outcomes to better inform patient choice and patients' quality of experience through engagement. •Support evidence-based purchasing of joint replacement implants for healthcare providers to support quality and cost effectiveness. •Support suppliers in the routine post-market surveillance of implants and provide information to clinicians, patients, hospital management and the regulatory authorities. Current Expectations - To be Defined Core service provision is expected to include: •Data systems and ingestion •Data processing and cleaning •Dynamic reporting and dashboards •Supplier feedback •Annual report statistical outputs •Outlier detection, reporting and analysis •PROMs and PREMs collection •Service desk and operational support Further details of the existing programme can be found at: https://www.njrcentre.org.uk/ For more information about this opportunity, please visit the eSourcing portal at: https://www.delta-esourcing.com/tenders/UK-UK-London:-Health-services./7449M9X8XA To respond to this opportunity, please click here: https://www.delta-esourcing.com/respond/7449M9X8XA

Portable Appliance Testing (PAT) for Lewisham and Greenwich NHS Trust

NHS England Specialised Commissioning (the "Contracting Authority”) is inviting suitably qualified and experienced suppliers to express an interest in providing Positron Emission Tomography – Computed Tomography (PET-CT) Services (all ages) and/or supplying the Tracers to providers of the Services, by responding to this opportunity. NHS Arden and Greater East Midlands CSU (AGCSU) is acting as an agent for and on behalf of the Contracting Authority and is supporting the ITT. PET-CT is a specialist diagnostic scan which is used extensively in cancer; it is also used in a relatively small number of other non-cancer specialties, such as neurology and infection and immunity. The scan itself involves the use of radioisotopes (or ‘tracers’) which are injected into the patient around an hour prior to the scan. Tracers can be grouped into those which are produced in cyclotron and hot cell facilities (‘standard tracers’), and those which typically need to be produced in radiopharmacy facilities that are co-located with scanners, due to radioactive half-life considerations (‘non-standard tracers’). Standard tracers account for >90% of PET-CT activity and almost all standard tracer scans involve FDG (a tracer). The single procurement opportunity will comprise two lots: Lot 1 - Scanning Services, including the optional supply of Gallium Non-Standard Tracers (NSTs) (the option will be procured by way of variant tenders as explained further below); and Lot 2 – Supply of Standard Tracers (STs). Each Lot will comprise of 12 identical Sub-Lots, enabling the pairing of Lot 1 and Lot 2 suppliers so that a complete PET-CT service is available to patients within those 12 Sub-Lot areas. On completion of the procurement, there will be 12 scanning services, which will together equate to c.50% of the NHS PET-CT market in England. The opportunity also includes a variant bid element within Lot 1, which will allow bidders to put forward proposals to establish up to 6 gallium scanning services nationally, i.e., 1 per NHS England Region included within the procurement opportunity. This is to enable increased access for patients to gallium scans. It is also proposed to future-proof the provision of amyloid scanning – this will only be activated within the Contracts in the event that approval is given for the use of disease modifying treatments for memory loss conditions and that those treatments require PET-CT amyloid scanning. This step has been taken to futureproof the Contracts for a potential, but not certain, service development. Form of contracts: The contracts to be entered into will be: Lot 1 - Scanning Services: Contracts will be entered into on the form of the NHS Standard Contract 2026/27. Where gallium is to be supplied as part of a consortium, the Contracting Authority will mandate a form of 'sub-contract' for use between the scanning services provider and the gallium supplier. Lot 2 - Standard Tracer Supply: Contracts will be entered into on the form of a bespoke supply of goods contract (as the NHS Standard Contract is not appropriate for a supply of goods contract). The form of contract will be mandated as a sub-contract between the scanning services provider in the relevant geography in Lot 1 and the standard tracer supplier in the corresponding geography in Lot 2. This model has been used previously to secure PET-CT provision. Direct Agreements – The Contracting Authority will also enter into a direct agreement with the successful standard tracer suppliers (to ensure proper flow down across all contracts linked to the procurement opportunity). Open procedure description: This procurement will follow an Open Procedure. This will be a single stage procurement where Bidders are asked to submit a response to the PSQ and ITT on the same date. Only bidders that pass the PSQ will have their tender response evaluated. No additional steps will be used. Following publication of this Tender Notice, bidders will be required to complete an EWA before receiving access to the Invitation to Tender (ITT). Completion of these will be a gateway requirement for access to the ITT, and bidders must submit their completed EWA within the timescales set out in this Tender Notice. Following confirmation of compliance, the ITT will be released simultaneously to all eligible bidders (see below) in early March 2026. Indicative procurement timeline (which is subject to change at NHSE’s discretion): • Tender Notice publication: 18/02/2026 • Access provided to EWA : 18/02/026 • Deadline for submission of EWA : 4/03/2026 • PSQ and ITT issued to all eligible bidders (see below): early March 2026 • Clarification question period deadline: mid-May 2026 • Final clarification question log issued: mid to late May 2026 • PSQ and ITT submission deadline: early June 2026 Eligible bidders are bidders who have received confirmation from NHSE that their submitted EWA has been counter-signed. Please allow approximately four (4) working days for the Contracting Authority to process your submission and confirm eligibility. The Contracting Authority may consider allowing late submission of the EWA , however in no circumstances can bidders submit this documentation after 06/03/2026 at 12:0hrs. Bidders who are late to submit their EWA documents will be required to submit their PSQ and ITT responses on the same date as bidders who submit their EWA documents on time. The PSQ will be assessed on a pass/fail basis covering legal, financial and technical requirements. Tenders from bidders that pass all PSQ criteria will then be evaluated. Bidders who fail the PSQ will be excluded and will not have their tenders evaluated. A clarification process will operate during the PSQ and ITT period to enable bidders to seek clarification from the Contracting Authority. Due diligence will be undertaken by the Contracting Authority prior to contract award to provide assurance that there are no material risks that could prevent contract signature i.e. if a Supplier bidding for the contract no longer meets the minimum standards required, and their Tender is rejected as a result, the Contracting Authority reserves the right to award the Contract to the next highest scoring Supplier. Please note the Contracting Authority reserves the right at any stage of the procurement to abandon the competition and not award a contract. The Contracting Authority also reserves the right to make minor amendments to the procurement documentation (for example, to clarify or refine requirements), provided such changes are not substantial and do not distort competition. If amendments are made, the Contracting Authority will consider whether any corresponding tender deadlines require revision and will issue updated documentation or notices where appropriate.

Provision of Liquid Nitrogen to the Wolfson Cellular Therapy Unit

NHS National Framework for Generics Pharmaceuticals Wave 16a Offer reference number: CM/PHG/24/5714 Period of framework agreement: Dates detailed below, with an option or options to extend (at the authority’s discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: CM/PHG/24/5714/01 Oral (plus non-parenteral) products: CESW/LSNE/NWLN: 1/02/2027 to 31/05/2030 (40 months) CM/PHG/24/5714/02 Hospital only products: DLN: 1/02/2027 to 31/01/2029 (24 months) DNW: 1/02/2027 to 31/01/2029 (24 months) CM/PHG/24/5714/03 Hospital only (housekeeping) products: DCE/DSW: 1/02/2027 to 30/09/2027 (8 months) DLS/DNE: 1/02/2027 to 31/05/2028 (16 months)

This framework is for Clinical and Pathology Microscopes and Related Accessories and Services including and not limited to those listed below. Precise quantities are unknown. It is anticipated that initial expenditure will be £22,518,282.00 (incl.VAT) in the first year of this Framework Agreement, however this is approximate only and the values may vary depending on the requirements of those bodies purchasing under the Framework Agreement. Estimated value over the total Framework Agreement term (including any extension options), is approximately £99,636,610.00 (incl. VAT). The intended Lot Structure for this procurement is set out as follows: • Lot 1 Theatre Microscopes and Related Accessories and Services • Lot 2 Outpatient Microscopes and Related Accessories and Services • Lot 3 Pathology Microscopes and Related Accessories and Services This procurement exercise will be conducted on the NHS Supply Chain eTendering portal at https://nhssupplychain.app.jaggaer.com//Candidates wishing to be considered for this contract must register their expression of interest and provide additional procurement-specific information (if required) through the NHS Supply Chain eTendering portal as follows: Registration. 1. Use URL https://nhssupplychain.app.jaggaer.com// to access the NHS Supply Chain Procurement portal. 2. If not yet registered:— Click on the ‘Not Registered Yet’ link to access the registration page.— Complete the registration pages as guided by the mini guide found on the landing page. Portal access. If registration has been completed:— Login with URL https://nhssupplychain.app.jaggaer.com// .— Click on ITTs Open to All Suppliers.— Select the following ITT: ITT_2207 - Clinical and Pathology Microscopes and Related Accessories and Services PSQ. ITT_2208 - Lot 1 Theatre Microscopes and Related Accessories and Services ITT_2209 - Lot 2 Outpatient Microscopes and Related Accessories and Services ITT_2210 - Lot 3 Pathology Microscopes and Related Accessories and Services Click on Express Interest. — If you intend to respond select Intend to Respond. Tenderers are encouraged to download the supplier handbook located within the eProcurement portal by following the 'Supplier Helpcentre' link within the Useful Links section of the Dashboard. For any technical help with the portal please contact: Tel: 800 069 8630 or email: help_uk@jaggaer.com Please refer to Section III.1.1 for additional information.

The Authority has a requirement for Principal Designer Services to take the lead in planning, managing, monitoring and coordinating health and safety during the pre-construction (design and planning stage) and during construction stages for the Cath Lab 3 refurbishment. The Authority wishes to engage with a principal designer to work closely with the project team, coordinating the work of others and ensuring significant and foreseeable risks are managed throughout the design process. The Authority wishes to engage with a principal designer to work closely with the project team, coordinating the work of others and ensuring significant and foreseeable risks are managed throughout the design process. The Project Guys and St Thomas’ NHS Foundation Trust (GSTT) are to replacing their existing Cardiac Catheter Laboratory medical equipment and refurbishing the existing facilities within Cardiac Catheter Laboratory (Cath Lab No.3) at 4th floor level of the East Wing of the St Thomas’ Hospital site. The Project has been designed and prepared to completion of RIBA 4.

The Home Office seeks to engage suppliers for the provision of healthcare services at short-term holding facilities and ports of entry across the UK. These services will support individuals whilst detained for short periods of time including in, but not limited to, Non Residential Short-Term Holding Facilities as defined under the Short Term Holding Facilities Rules 2018 (as amended), where individuals can be held up to 24 hours. The Authority is seeking a flexible, responsive and value for money healthcare solution that meets the basic needs of individuals and can be flexible to different service environments; the short-term holding facilities are located at different location types across the UK which include Airports, Seaports, and Reporting Centres. This market engagement aims to understand supplier capabilities, to further refine the Authority’s specification and gather feedback on proposed approaches which could include onsite and/or remote health services. The content of this Notice, including the nature of services and the start date of the contract, is subject to change. The contract is expected to commence in late 2027/early 2028. The length of contract has not been confirmed yet. For the purposes of this Preliminary Market Engagement Notice, the estimated contract value has been listed as £0. This figure does not reflect the expected final value of the contract. The actual estimated value is currently being finalised and will be shared later.

The Integrated Non‑Custodial Services(INCS) will be required to deliver a continuous, coordinated, and seamless model of non‑custodial criminal justice healthcare and support. The service will meet individuals identified health and wellbeing needs while addressing factors associated with offending behaviour, with a focus on early intervention, continuity of care, and improved outcomes across the criminal justice pathway.<br/><br/>The ITT documentation should be completed by 2pm on the 12 June 2026. The ITT reference is C443325.

This procurement seeks to commission three accredited Master’s-level paediatric audiology modules, delivered by higher education institutions and mapped to the British Academy of Audiology (BAA) Higher Training Scheme (HTS): Newborn Auditory Brainstem Response (ABR) Assessment; Visual Reinforcement Audiometry (VRA, 6 months+); and Paediatric Habilitation and Family-Centred Care. Lot 1: Newborn Auditory Brainstem Response (ABR) Assessment (£138,000 max value) One provider will be awarded under lot one. Lot 2: Visual Reinforcement Audiometry (VRA) for infants aged 6 months and above (£229,500 max value) Lot 3: Paediatric Habilitation and Family-Centred Care (£262,500 max value) Up to two providers will be awarded under lots 2&3. Places will be split equally between the two supplier, if there is an uneven number of places the first ranked supplier will be given the extra place. If only one supplier is awarded they will be awarded all the places under that lot. Suppliers may bid for more than one lot. This will be a three year contracts with optional 12 month extension. Total funding available is £630,000 This will train up to 420 learners across all lots over the length of the contract. Price per learner per module is a maximum of £1500. The deadline for submission of completed ITQ submissions is 12th June 2026 at 12:00pm (midday). Late submissions will not be accepted therefore, please submit in good time prior to the deadline date and time. All communications should be made via the messaging function on the e-Tendering portal during the tender exercise. The Contracting Authority requests that all communications are channelled through the e-portal system and not with the Contracting Authority itself other than as expressly permitted within this ITQ. Further information relating to this project can be found at NHSE e-tendering portal at the link below. All clarification questions and submission bids must be received via this portal only. Registration is free of charge. https://health-family-contract-search.secure.force.com/?SearchType=Projects

Provision of Level 4 accredited GPA training including learner support, mentorship guidance, portfolio assessment, accreditation, quality assurance, reporting, and collaborative working with regional Training Hubs. The estimated value of the Contract(s) over a maximum 5 year term is the maximum expenditure that the Contracting Authority has budgeted for payment under the Contract(s). Including all extensions this is £13,749,255.00 (Exclusive of VAT). The Awarded Contracts shall be payable based on the volume of activity with a maximum price per learner of £3,711.00 (Exclusive of VAT). The initial contract term shall be 3 years with the potential for 2 years in Contract extension periods by election of the Contracting Authority, on such notice and for such periods as is specified by the Contract. The Contracting Authority anticipates that it will enter into a contract with between 1 to 7 providers. The deadline for submission of completed ITT submissions is 12th June 2026 at 12:0pm (midday). Late submissions will not be accepted therefore, please submit in good time prior to the deadline date and time. All communications should be made via the messaging function on the e-Tendering portal during the tender exercise. The Contracting Authority requests that all communications are channelled through the e-portal system and not with the Contracting Authority itself other than as expressly permitted within this ITT. Further information relating to this project can be found at NHSE e-tendering portal at the link below. All clarification questions and submission bids must be received via this portal only. Registration is free of charge. https://health-family-contract-search.secure.force.com/?SearchType=Projects